Published in JAKSTAT on August 19, 2013
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Front Oncol (2015) 0.89
Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res (2015) 0.80
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel) (2015) 0.79
Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. BMC Mol Biol (2016) 0.78
The natural chemopreventive agent sulforaphane inhibits STAT5 activity. PLoS One (2014) 0.78
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol (2007) 11.48
Cooperation between complexes that regulate chromatin structure and transcription. Cell (2002) 10.38
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood (2001) 6.35
Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell (1999) 4.69
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell (2007) 4.46
A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev (1995) 4.11
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 3.66
Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol (2008) 3.56
Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol (1998) 3.23
STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J (1999) 3.14
JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol (2008) 2.85
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81
Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia (2012) 2.80
DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett (2012) 2.69
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene (2007) 2.67
Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell (2009) 2.39
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Mast cells and mastocytosis. Blood (2008) 2.32
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol (2009) 2.05
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol (2011) 2.05
A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev (2009) 1.98
IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J Exp Med (2005) 1.94
STATs dimerize in the absence of phosphorylation. J Biol Chem (2003) 1.89
Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol (2008) 1.79
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A (2008) 1.73
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A (2010) 1.72
Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma chain-deficient mice. Immunity (1997) 1.71
Acetylation-dependent signal transduction for type I interferon receptor. Cell (2007) 1.68
DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol (2000) 1.68
Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets (2006) 1.63
The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol (1999) 1.62
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett (2010) 1.59
Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood (2009) 1.58
SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem (1999) 1.56
Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta (2011) 1.56
STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J (2003) 1.53
Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem (2004) 1.50
Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol (2006) 1.50
Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol Chem (1999) 1.49
Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation. J Biol Chem (1996) 1.48
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood (2008) 1.47
Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal (2009) 1.40
Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J (2001) 1.39
Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol (2012) 1.36
Structure of the unphosphorylated STAT5a dimer. J Biol Chem (2005) 1.32
HDACi--targets beyond chromatin. Cancer Lett (2009) 1.32
IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood (2010) 1.31
Modulation of the IL-7 dose-response threshold during pro-B cell differentiation is dependent on pre-B cell receptor expression. J Immunol (1998) 1.31
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett (2009) 1.29
Hsp90: structure and function. Top Curr Chem (2013) 1.27
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta (2010) 1.26
Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J (2004) 1.24
Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol (2003) 1.24
Transcription factor miz-1 is required to regulate interleukin-7 receptor signaling at early commitment stages of B cell differentiation. Immunity (2010) 1.21
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
SOCS1 links cytokine signaling to p53 and senescence. Mol Cell (2009) 1.18
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012) 1.16
HDAC2: a critical factor in health and disease. Trends Pharmacol Sci (2009) 1.15
Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol (2009) 1.13
Diagnostic complexities of eosinophilia. Arch Pathol Lab Med (2013) 1.12
SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 1.11
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood (2010) 1.11
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood (2008) 1.10
Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther (2007) 1.10
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood (2009) 1.09
Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality. Blood (2009) 1.08
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res (2008) 1.08
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res (2011) 1.06
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer (2012) 1.05
A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol (2011) 1.05
Therapeutic targeting of c-KIT in cancer. Expert Opin Investig Drugs (2012) 1.05
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem (2012) 1.03
Acetylation modulates prolactin receptor dimerization. Proc Natl Acad Sci U S A (2010) 1.01
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res (2011) 1.01
Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J Immunol (2008) 1.01
Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia (2010) 0.99
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J (2007) 0.99
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog (2011) 0.99
Inhibitors of HDACs--effective drugs against cancer? Curr Cancer Drug Targets (2010) 0.98
SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) (2010) 0.98
IL-7R-dependent survival and differentiation of early T-lineage progenitors is regulated by the BTB/POZ domain transcription factor Miz-1. Blood (2011) 0.98
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle (2011) 0.97
Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev (2012) 0.97
The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica (2009) 0.96
Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology (2009) 0.96
SIAH proteins: critical roles in leukemogenesis. Leukemia (2012) 0.96